Literature DB >> 2566625

Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.

B Pecha1, D Low, P O'Hanley.   

Abstract

The initial pathogenic step in nonobstructive Escherichia coli pyelonephritis usually involves the binding of a bacterial adhesin with host uroepithelial glycoprotein receptors containing the D-Gal p alpha 1----4 D-Gal p beta 1 (Gal-Gal) moiety. In this study, groups of mice were immunized with Gal-Gal pili and challenged 2 wk later intravesicularly with E. coli strains expressing homologous or heterologous pili. 63 of 129 pili-immunized mice (49%) were protected from subsequent E. coli renal colonization compared with 5 of 85 control mice (6%). Among mice that had E. coli cultured from their right kidney, control mice had greater bacterial colony counts than pili-immunized animals (P less than 0.05). Light microscopic examination of kidneys demonstrated less histopathology among pili immunized mice than among control mice (P less than 0.05). Protection correlated with the presence of specific IgG antibodies in the urine and serum that bind to the major pilin structural polypeptide and not to the Gal-Gal pili tip adhesin per se. These results support the concept that immunization with a bacterial surface-coat constituent can prevent mucosal infection by interfering with colonization. Also Gal-Gal pili of E. coli represent a suitable candidate for immunoprophylaxis against pyelonephritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566625      PMCID: PMC303937          DOI: 10.1172/JCI114123

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model.

Authors:  M A Schmidt; P O'Hanley; D Lark; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Localization of the receptor-binding protein adhesin at the tip of the bacterial pilus.

Authors:  F Lindberg; B Lund; L Johansson; S Normark
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

3.  Prevention of pyelonephritis by immunization with P-fimbriae.

Authors:  J A Roberts; K Hardaway; B Kaack; E N Fussell; G Baskin
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

4.  Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli.

Authors:  P O'Hanley; D Low; I Romero; D Lark; K Vosti; S Falkow; G Schoolnik
Journal:  N Engl J Med       Date:  1985-08-15       Impact factor: 91.245

5.  Gene products specifying adhesion of uropathogenic Escherichia coli are minor components of pili.

Authors:  F Lindberg; B Lund; S Normark
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.

Authors:  P O'Hanley; D Lark; S Falkow; G Schoolnik
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

7.  Six widespread bacterial clones among Escherichia coli K1 isolates.

Authors:  M Achtman; A Mercer; B Kusecek; A Pohl; M Heuzenroeder; W Aaronson; A Sutton; R P Silver
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

8.  Mannose-sensitive and Gal-Gal binding Escherichia coli pili from recombinant strains. Chemical, functional, and serological properties.

Authors:  P O'Hanley; D Lark; S Normark; S Falkow; G K Schoolnik
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

9.  Gal-Gal pyelonephritis Escherichia coli pili linear immunogenic and antigenic epitopes.

Authors:  M A Schmidt; P O'Hanley; G K Schoolnik
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

10.  Mutations in E coli cistrons affecting adhesion to human cells do not abolish Pap pili fiber formation.

Authors:  M Norgren; S Normark; D Lark; P O'Hanley; G Schoolnik; S Falkow; C Svanborg-Edén; M Båga; B E Uhlin
Journal:  EMBO J       Date:  1984-05       Impact factor: 11.598

View more
  26 in total

1.  Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.

Authors:  K Thankavel; B Madison; T Ikeda; R Malaviya; A H Shah; P M Arumugam; S N Abraham
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Frequency and organization of papA homologous DNA sequences among uropathogenic digalactoside-binding Escherichia coli strains.

Authors:  K Denich; A Craiu; H Rugo; G Muralidhar; P O'Hanley
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.

Authors:  Pawel Goluszko; Elzbieta Goluszko; Bogdan Nowicki; Stella Nowicki; Vsevolod Popov; Hui-Qun Wang
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

5.  Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics.

Authors:  D E Neal; M B Kaack; G Baskin; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG.

Authors:  J R Johnson; A E Stapleton; T A Russo; F Scheutz; J J Brown; J N Maslow
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 7.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

8.  Urethral obstruction of 6 hours or less causes bacteriuria, bacteremia, and pyelonephritis in mice challenged with "nonuropathogenic" Escherichia coli.

Authors:  D E Johnson; R G Russell; C V Lockatell; J C Zulty; J W Warren
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  Adhesive threads of extraintestinal pathogenic Escherichia coli.

Authors:  Esther-Maria Antão; Lothar H Wieler; Christa Ewers
Journal:  Gut Pathog       Date:  2009-12-10       Impact factor: 4.181

10.  Signature-tagged mutagenesis in a chicken infection model leads to the identification of a novel avian pathogenic Escherichia coli fimbrial adhesin.

Authors:  Esther-Maria Antão; Christa Ewers; Doreen Gürlebeck; Rudolf Preisinger; Timo Homeier; Ganwu Li; Lothar H Wieler
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.